Trial Profile
A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evocalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jun 2014 New trial record